Even with looming generic competition expected to take a big bite out of sales of its blockbuster Advair, respiratory drugs remain key to GlaxoSmithKline, and it continues to plow money into their ...
Even after going off patent in some markets, GlaxoSmithKline's Advair looked like the gift that would keep on giving. Its sophisticated inhaler device made it difficult to copy, protecting sales of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results